NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Forecast, Price & News

$24.14

-0.41 (-1.67%)

(As of 09/21/2023 ET)

Compare

Today's Range: $23.50
▼
$24.45
50-Day Range: $24.55
▼
$31.38
52-Week Range: $21.04
▼
$34.16

Volume: 672,073 shs
Average Volume: 489,993 shs
Market Capitalization: $1.51 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $50.50

SpringWorks Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 109.2% Upside
$50.50 Price Target
Short Interest: Bearish
23.22% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$70,872 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.19) to ($4.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

759th out of 965 stocks

Biological Products, Except Diagnostic Industry

120th out of 159 stocks

3.5

Analyst's Opinion

Consensus Rating
SpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $50.50, SpringWorks Therapeutics has a forecasted upside of 109.2% from its current price of $24.14.
Amount of Analyst Coverage
SpringWorks Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
23.22% of the outstanding shares of SpringWorks Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
SpringWorks Therapeutics has a short interest ratio ("days to cover") of 24.7, which indicates bearish sentiment.
Change versus previous month
Short interest in SpringWorks Therapeutics has recently decreased by 3.71%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
SpringWorks Therapeutics does not currently pay a dividend.
Dividend Growth
SpringWorks Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SWTX.

2.7

News and Social Media Coverage

News Sentiment
SpringWorks Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for SpringWorks Therapeutics this week, compared to 2 articles on an average week.
Search Interest
5 people have searched for SWTX on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $70,872.00 in company stock.
Percentage Held by Insiders
Only 7.43% of the stock of SpringWorks Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($5.19) to ($4.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SpringWorks Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SpringWorks Therapeutics is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SpringWorks Therapeutics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SpringWorks Therapeutics (NASDAQ:SWTX) Stock

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Price History

30 days | 90 days | 365 days | Advanced Chart

SWTX Stock News Headlines

September 11, 2023 | msn.com

SpringWorks Therapeutics gets new chief scientific officer

September 11, 2023 | markets.businessinsider.com

SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

September 22, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

August 24, 2023 | markets.businessinsider.com

SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update

August 24, 2023 | msn.com

HC Wainwright & Co. Reiterates SpringWorks Therapeutics (SWTX) Buy Recommendation

August 21, 2023 | seekingalpha.com

SpringWorks down 6% on alleged violation of trial protocols

August 8, 2023 | msn.com

HC Wainwright & Co. Maintains SpringWorks Therapeutics (SWTX) Buy Recommendation

August 2, 2023 | finanznachrichten.de

SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

September 22, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

August 2, 2023 | finance.yahoo.com

SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

July 20, 2023 | msn.com

Goldman Sachs Maintains SpringWorks Therapeutics (SWTX) Buy Recommendation

July 19, 2023 | markets.businessinsider.com

Goldman Sachs Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)

July 12, 2023 | seekingalpha.com

SpringWorks Therapeutics: FDA Decision Date Ahead

July 1, 2023 | fool.com

SpringWorks Therapeutics (NASDAQ: SWTX)

June 28, 2023 | finance.yahoo.com

Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 ‘Strong Buy’ Names With Solid Upside Potential

June 7, 2023 | finance.yahoo.com

SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

June 7, 2023 | msn.com

HC Wainwright & Co. Reiterates SpringWorks Therapeutics (SWTX) Prior Recommendation

June 6, 2023 | msn.com

The Latest Analyst Ratings for SpringWorks Therapeutics

June 5, 2023 | markets.businessinsider.com

Barclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)

June 5, 2023 | msn.com

FDA extends action deadline for SpringWorks nirogacestat drug application

June 5, 2023 | reuters.com

US FDA delays decision on SpringWorks Therapeutics' tumor treatment

June 5, 2023 | markets.businessinsider.com

SpringWorks: FDA Extends PDUFA Date For Nirogacestat NDA

June 5, 2023 | marketwatch.com

SpringWorks Therapeutics: FDA Extends Review of Nirogacestat >SWTX

June 5, 2023 | finance.yahoo.com

SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA

May 30, 2023 | finance.yahoo.com

SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

May 25, 2023 | finance.yahoo.com

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

May 11, 2023 | finance.yahoo.com

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

See More Headlines

Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SWTX Company Calendar

Last Earnings: 8/02/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SWTX
CUSIP: N/A
CIK: 1773427
Web: www.springworkstx.com
Phone: 203-883-9490
Fax: N/A
Employees: 227
Year Founded: 2017

Price Target and Rating

Average Stock Price Forecast: $50.50
High Stock Price Forecast: $66.00
Low Stock Price Forecast: $41.00
Forecasted Upside/Downside: +109.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-277,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -55.98%
Return on Assets: -49.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.55
Quick Ratio: 11.55

Sales & Book Value

Annual Sales: $35 million
Price / Sales: 43.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.95 per share
Price / Book: 2.70

Miscellaneous

Outstanding Shares: 62,570,000
Free Float: 57,921,000
Market Cap: $1.51 billion
Optionable: Not Optionable
Beta: 0.58

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Saqib Islam J.D. (Age 53)
CEO & Director
Comp: $1.26M

Mr. Francis I. Perier Jr. (Age 63)
M.B.A., Chief Financial Officer
Comp: $710.6k

Dr. Badreddin Edris Ph.D. (Age 36)
Chief Operating Officer
Comp: $998.61k

Dr. L. Mary Smith PH.D. (Age 56)
Chief Devel. Officer
Comp: $817.17k

Mr. Bhavesh Ashar (Age 57)
Chief Commercial Officer
Comp: $729.62k

Mr. Michael P. Nofi (Age 52)
Chief Accounting Officer

Ms. Kim Diamond
VP of Communications & Investor Relations

Mr. Herschel S. Weinstein J.D. (Age 67)
Gen. Counsel & Sec.

Mr. Daniel J. Pichl (Age 40)
Chief People Officer

Dr. James Cassidy M.D. (Age 64)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SWTX Stock - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings or view top-rated stocks.
What is SpringWorks Therapeutics' stock price forecast for 2023?: 4 Wall Street research analysts have issued 12 month target prices for SpringWorks Therapeutics' stock. Their SWTX share price forecasts range from $41.00 to $66.00. On average, they predict the company's share price to reach $50.50 in the next year. This suggests a possible upside of 109.2% from the stock's current price.
View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts.
How have SWTX shares performed in 2023?: SpringWorks Therapeutics' stock was trading at $26.01 at the beginning of 2023. Since then, SWTX shares have decreased by 7.2% and is now trading at $24.14.
View the best growth stocks for 2023 here.
When is SpringWorks Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our SWTX earnings forecast.
How were SpringWorks Therapeutics' earnings last quarter?: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.01. During the same quarter in the prior year, the business earned ($1.41) EPS.
What ETFs hold SpringWorks Therapeutics' stock?: ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).
What other stocks do shareholders of SpringWorks Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI).
When did SpringWorks Therapeutics IPO?: (SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is SpringWorks Therapeutics' stock symbol?: SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."
Who are SpringWorks Therapeutics' major shareholders?: SpringWorks Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.81%), Deep Track Capital LP (5.67%), State Street Corp (5.04%), ArrowMark Colorado Holdings LLC (3.99%), Artal Group S.A. (2.90%) and Perceptive Advisors LLC (2.46%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto.
View institutional ownership trends.
How do I buy shares of SpringWorks Therapeutics?: Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is SpringWorks Therapeutics' stock price today?: One share of SWTX stock can currently be purchased for approximately $24.14.
How much money does SpringWorks Therapeutics make?: SpringWorks Therapeutics (NASDAQ:SWTX) has a market capitalization of $1.51 billion and generates $35 million in revenue each year. The company earns $-277,420,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis.
How many employees does SpringWorks Therapeutics have?: The company employs 227 workers across the globe.
Does SpringWorks Therapeutics have any subsidiaries?: The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..
Read More
How can I contact SpringWorks Therapeutics?: SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The official website for the company is www.springworkstx.com. The company can be reached via phone at 203-883-9490 or via email at investors@springworkstx.com.

This page (NASDAQ:SWTX) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial